LEADS BIOLABS-B

9887
33.2605.30% ( -1.860 )
Delay Closed: Nov 16, 16:08:11

Overview

LEADS BIOLABS-B (9887)

Nanjing Leads Biolabs Co., Ltd., a clinical-stage biotechnology company, engages in the research, development, and commercialization of novel antibody drugs wor...

Open
35.000
High
35.000
Low
32.740
Prev. Close
35.120
Volume
1.17M
Turnover
38.97M
Avg Price
33.269
Bid/Ask Ratio
70.37%
Amplitude
6.44%
52wk High
97.500
Volume Ratio
1.05
Turnover Ratio
0.59%
52wk Low
32.740
HK Mkt Cap
6.57B
Market CapHKD
6.62B
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-1.55
EPSDynamic
-2.57
EPSStatic
--
BVPS
5.39
P/B
6.17
HK Shares
197.67M
Dividend YieldTTM
--
DividendTTM
--
Shares
198.89M
Min lot size
100
Currency
HKD

LEADS BIOLABS-B Analyst Rating

View more

Forecast & Rating

Oct 15, 2026
Price forecast
HK$105.70217.80%
Forecast & RatingStrong buy
6analysts
  • Strong buy66.67%
  • Buy33.33%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 16

    Extending the prior session's near-7% slide, the stock closed down 5.30% at HK$33.26 after spiking and fading: it opened at HK$35.00 and sank to a fresh 52-week low of HK$32.74 by 10:16 BJ, then traded narrowly around HK$33.0 through the afternoon on 1.17 million shares worth about HK$38.97 million. A dense run of clinical updates, including LBL-024's 8.7-month median survival in late-line EP-NEC, LBL-034's 21.8-month mPFS in RRMM, the first SLE patient dosed with LBL-047 and a second FDA Fast Track, failed to reverse the decline, while Q2 revenue of HK$20.77 million came alongside a HK$128.17 million net loss that widened 28.5% year-on-year at a -617% net margin. The shares are down 34.14% year-to-date, 65.89% below the 15 April high of HK$97.5, and sit under the MA20 of HK$37.03 and MA60 of HK$50.59. CLSA nonetheless pointed to improving overseas and domestic trends in China healthcare.

  2. Nov, 13

    维立志博-B 今日冲高回落,以 37.46 港元平开后单边走弱,14:51 下探 34.92 港元,收 35.02 港元、跌约 6.3%,成交 2889 万港元,换手率 0.41%。LBL-024 在胆道癌取得 55% 缓解率、拿到第二项 FDA 快速通道,以及 LBL-047 完成 SLE 首例给药等进展,都未能支撑股价;Q2 2026 净亏损扩大 28.5% 至 1.282 亿港元,收入仅 2077 万港元,EPS -0.6505 港元,对应 PE -22.73、PB 6.52。现价 35.12 港元低于 MA20 37.43 与 MA60 51.31,年内跌 30.46%,较 52 周高点 97.5 港元低 63.98%,距 33.66 港元低点仅 4.34%。CLSA 称中国医疗板块回调是买入机会,不过公司仍处亏损且股价受制于两条均线。

  3. Nov, 10

    Carrying over ESMO pipeline readouts and the first SLE patient dosed with LBL-047, plus a weekly recap showing most brokers rate the stock buy, 9887.HK reversed early weakness, sliding to HK$37.44 in the morning session before an afternoon push to HK$39.80, and closed up 3.71% at HK$39.08 on HK$47.16 million turnover. The 21.8-month median PFS for LBL-034 in relapsed/refractory multiple myeloma remains the main anchor for sentiment. Fundamentals are still at a pre-commercial scale: Q2 revenue of HK$20.77 million against a net loss of HK$128.17 million, 28.5% wider year on year, with loss per share of HK$0.6505. The stock has reclaimed its MA20 of HK$38.22 but sits well below the MA60 of HK$53.09, 59.92% below the April 15 high of HK$97.50 and down 22.61% year to date, though still 16.1% above the November 3 low of HK$33.66. Shareholder Nanjing Lizhi nonetheless trimmed 16,500 shares at about HK$43.67, and a 0.62% turnover rate shows no volume confirmation.

  4. Nov, 9

    Leads Biolabs rose 3.06% to HK$37.68 after opening at HK$37.88, spiking to an intraday high of HK$38.56 at 10:58 in the morning session before fading through the afternoon, following the first systemic lupus erythematosus patient dosed in Part B of the Phase I study of LBL-047, a BDCA2/TACI bifunctional fusion protein, alongside ESMO 2026 data showing 21.8-month mPFS for LBL-034 and 8.7-month median survival for LBL-024. That clinical cadence contrasts with the financials: Q2 2026 revenue was only HK$20.77 million while the net loss widened 28.5% year on year to HK$128.17 million, with ROE at -47.68%. The shares remain below the MA20 of HK$38.54 and the MA60 of HK$53.66, down 25.39% year to date and 61.35% below the 52-week high of HK$97.5, though they sit 11.94% above the 52-week low of HK$33.66 set on 3 November.

  5. Nov, 6

    Leads Biolabs-B closed down 4.19% at HK$36.56 in a spike-and-fade session, having touched HK$37.44 at 09:53 before losing momentum and probing HK$36.20 in the afternoon, staying below the prior close of HK$38.16. The tape continued to absorb October ESMO data, including an 8.7-month median survival for LBL-024 in late-line EP-NEC and a 21.8-month mPFS for LBL-034 in RRMM, plus the first SLE patient dosed in Part B of the Phase I trial of LBL-047, a BDCA2/TACI bifunctional fusion protein; offsetting that, Nanjing Lizhi Enterprise Management Consulting Center sold 16,500 shares at about HK$43.67, and the stock is down 27.6% year to date, 62.5% below its 52-week high of HK$97.50 and just 8.62% above the HK$33.66 low. Q2 EPS of -HK$0.6505 and a net loss of HK$128 million widening 28.5% year on year, with a -617% net margin and a -23.66x PE, leave the price below its MA20 of HK$38.94 and MA60 of HK$54.18; though CLSA sees improving overseas and domestic trends creating opportunity after the China healthcare pullback.

News

Bullish vs. Bearish — Last 3 Months

13.9k followers · 0 opinions
▲Bullish50%
50%Bearish▼
  • M
    momoM

    $LEADS BIOLABS-B(09887.HK) got 3 lots and sold 2 lots, thanks to Longbridge and the new stock.

    图片 1,共 1 张
  • M
    momoM

    $LEADS BIOLABS-B(09887.HK) Let's go all in $DUALITYBIO-B(09606.HK) hoping to replicate the trend.

    图片 1,共 1 张